Membrane transporters P-glycoprotein [P-gp; multidrug resistance 1 (MDR1)], multidrug resistance-associated protein (MRP) 2, and breast cancer resistance protein (BCRP) affect drug absorption and disposition and can also mediate drug-drug interactions leading to safety/toxicity concerns in the clinic. Challenges arise with interpreting cell-based transporter assays when substrates or inhibitors affect more than one actively expressed transporter and when endogenous or residual transporter activity remains following overexpression or knockdown of a given transporter. The objective of this study was to selectively knock out three drug efflux transporter genes (MDR1, MRP2, and BCRP), both individually as well as in combination, in a subclone of Caco-2 cells (C2BBe1) using zinc finger nuclease technology. The wild-type parent and knockout cell lines were tested for transporter function in Transwell bidirectional assays using probe substrates at 5 or 10 mM for 2 hours at 37°C. P-gp substrates digoxin and erythromycin, BCRP substrates estrone 3-sulfate and nitrofurantoin, and MRP2 substrate 5-(and-6)-carboxy-29,79-dichlorofluorescein each showed a loss of asymmetric transport in the MDR1, BCRP, and MRP2 knockout cell lines, respectively. Furthermore, transporter interactions were deduced for cimetidine, ranitidine, fexofenadine, and colchicine. Compared with the knockout cell lines, standard transporter inhibitors showed substrate-specific variation in reducing the efflux ratios of the test compounds. These data confirm the generation of a panel of stable Caco-2 cell lines with single or double knockout of human efflux transporter genes and a complete loss of specific transport activity. These cell lines may prove useful in clarifying complex drug-transporter interactions without some of the limitations of current chemical or genetic knockdown approaches.
Introduction
Membrane drug transporters play an important role in the distribution of endogenous molecules and xenobiotics throughout the body and are implicated in detoxification mechanisms as well as multidrug resistance. Members of the ATP-binding cassette (ABC) efflux transporter family, such as P-glycoprotein [P-gp; multidrug resistance 1 (MDR1); ABCB1], multidrug resistance-associated protein (MRP) 2 (ABCC2), and breast cancer resistance protein (BCRP; ABCG2), actively efflux a wide variety of small-molecule substrates out of the cell to protect cells and organs against harmful drugs or toxins (Litman et al., 2001; Shitara et al., 2006) . ABC transporters have a protective role in blocking intestinal absorption (Takano et al., 2006; Oude Elferink and de Waart, 2007) and enhancing excretion of endogenous and xenobiotic compounds from the hepatic canalicular membrane and the kidney proximal tubules (Köck and Brouwer, 2012; Masereeuw and Russel, 2012) . They play a role in clinical drug resistance to multiple chemotherapeutic agents (Szakacs et al., 2006; Veringa et al., 2013) and in drug-drug interactions that may alter systemic exposure and lead to clinical adverse events (Lin, 2007; Marquez and Van Bambeke, 2011; Müller and Fromm, 2011; DeGorter et al., 2012) .
Guidelines have recently been published by the US Food and Drug Administration (http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf) and European Medicines Agency (http://www.ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/2012/07/WC500129606.pdf) on screening new chemical entities for interactions with clinically relevant transporters. In vitro evaluation of specific transporter interactions can employ a variety of tools, including transporter-expressing cell lines, membrane vesicles, and tissues, along with a panel of substrates and inhibitors as control probes. The standard assay format for ABC transporter function measures the transcellular permeability of a test article through a monolayer of cells grown on a permeable filter, and comparison of the absorptive versus secretory flux. Caco-2 cells are derived from a human intestinal adenocarcinoma and are widely used as a model of intestinal absorption and transporter activity (Elsby et al., 2008) . These cells differentiate in culture to an intestinal phenotype with a well defined apical brush border, are able to form tight junctions, and express the ABC efflux transporters P-gp, BCRP, and MRP2, as well as other uptake and efflux transporters normally expressed in human intestinal enterocytes (Hilgendorf et al., 2007) . The cells express the transporters in a polarized fashion, enabling the vectorial transport of substrates, and are considered the gold standard for efflux transporter screening.
Transporters recognize and interact with a broad range of compounds based on their physicochemical characteristics (Didziapetris et al., 2003; Zhou et al., 2008) , with overlapping substrate recognition between transporters. Transporter-"specific" inhibitors are used to help define interactions, but may also show overlapping interactions between transporters (Matsson et al., 2009) . In addition, substrates may interact with different binding sites per transporter, necessitating the use of multiple inhibitors with different binding site-specific affinities for each transporter (Giri et al., 2009 ). This lack of specificity can cause misinterpretation in biologic systems with multiple transporters or endogenous transporters in transfected cell lines (Goh et al., 2002; Wang et al., 2008; Mease et al., 2012) . Thus, there exists a need for human testing systems that allow unambiguous identification of specific substrate interaction without dependence on chemical inhibition.
Targeted suppression of gene expression by RNA interference techniques has been explored in several laboratories using Caco-2 cells (Celius et al., 2004; Watanabe et al., 2005; Zhang et al., 2009; Darnell et al., 2010; Graber-Maier et al., 2010) . Transfection of short hairpin RNA vectors and the resultant downregulation of transporters offers an advantage over reliance on inhibitors to elucidate specific drug-transporter interactions. However, not all RNA oligos are able to knock down the targeted mRNA efficiently, and they may invoke offtarget effects on similar mRNAs. Most importantly, substantial residual activity may remain in a cell line in spite of reduced mRNA and protein levels (Darnell et al., 2010; Wang et al., 2014) .
Zinc finger nuclease (ZFN) technology involves transfection of highly specific gene-targeting reagents linked to DNA cleavage enzymes, allowing exquisite specificity and total gene knockout (KO) in a stable cell line while minimizing off-target effects (Santiago et al., 2008) . We report here the generation and characterization of a panel of KO cell lines targeting MDR1, BCRP, and MRP2 transporters in the Caco-2 subclone C2BBe1 cell line using ZFNs. The resultant panel of single or double KO cells shows disruption of gene sequence as well as complete loss of transporter function in bidirectional transport assays. These transporter KO cell lines provide a powerful new tool for elucidating transporter interactions.
Materials and Methods
Unless otherwise indicated, all cell culture media, biochemical reagents, and chemicals were obtained from Sigma-Aldrich (St. Louis, MO). Costar Transwell HTS 24-well plates were purchased from Sigma-Aldrich. 5-(and-6)-Carboxy-29,79-dichlorofluorescein (CDCF) and 5-(and-6)-carboxy-29,79-dichlorofluorescein diacetate (CDCFDA) were purchased from Life Technologies (Carlsbad, CA). Primers specific for MDR1, BCRP, MRP2-4 transporter genes, and the endogenous control human glyceraldehyde-3-phosphate dehydrogenase gene were purchased as Taqman Gene Expression Assays from Life Technologies. For Western blotting experiments, a rabbit monoclonal antibody to MDR1 and a mouse monoclonal antibody to b-actin were purchased from Abcam Inc. (Cambridge, MA), while rabbit polyclonal antibody to BCRP and rabbit monoclonal antibody to MRP2 were obtained from Cell Signaling Technology, Inc. (Danvers, MA). Secondary antibodies for b-actin (donkey anti-mouse) and transporters (donkey anti-rabbit) were obtained from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA).
Cell Culture. The C2BBe1 (Caco-2 brush border-expressing) cell line, a subclone of Caco-2 cells, was obtained from American Type Culture Collection (Manassas, VA). The original tissue donor was a 72-year-old male with colorectal adenocarcinoma. The C2BBe1 cell line had been cloned from the Caco-2 cell line (ATCC HTB-37) by limiting dilution and was selected on the basis of morphologic homogeneity and exclusive apical villin localization (Peterson and Mooseker, 1992) . Cells were maintained in high-glucose Dulbecco's modified Eagle's medium with 10% heat-inactivated fetal bovine serum, 1% (v/v) minimum Eagle's medium nonessential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, and 100 mg/ml streptomycin. Cells were cultured in humidified incubators at 37°C in 5% CO 2 . Culture medium was refreshed at 2-to 3-day intervals. Cells were passaged upon reaching confluence, at least once per week, using 0.25% trypsin-EDTA.
ZFN-Mediated DNA Modification and Subclone Selection. KO cell lines were generated using CompoZr Custom Zinc Finger Nuclease (Sigma-Aldrich) kit components as previously described (Pratt et al., 2012) . Briefly, 2 mg of each ZFN forward and reverse mRNA primer for each transporter gene, along with 4 mg of gene-specific mammalian single-strand annealing reporter plasmids containing two complementary portions of the green fluorescent protein, were nucleofected into C2BBe1 cells using the Amaxa Cell Line Nucleofector Kit T for Caco-2 cells (Lonza, Basel, Switzerland) as per the manufacturer's directions. Nucleofected cells were immediately placed in 20% fetal bovine serum growth medium and cultured in six-well plates at 30°C for 2 days to increase efficiency of nucleofection, then were moved to 37°C. Medium was refreshed once cells had attached. After growing to .70% confluence (1-2 weeks), cells were trypsinized and stained with 1 mg/ml of propidium iodide before flow cytometry sorting based on green fluorescent protein-positive (indicating successful ZFN cutting) and propidium iodidenegative (indicating viable cells) sort gates. Cells were single cell sorted into 96-well plates using the FACSAria III (BD Biosciences, San Jose, CA) and were cultured for several weeks to form substantial colonies before testing for mutations. Genomic DNA was obtained using QuickExtract DNA Extraction Solution (Epicentre Biotechnologies, Madison, WI) and scaled up using polymerase chain reaction (PCR) amplification with the ZFN Cel-1 primers specific for each target gene. PCR product was run on the 96-capillary 3730xl DNA Analyzer using Peak Scanner software v1.0 (Life Technologies). Clones showing non-wild-type and out-of-frame mutations were selected for subcloning. DNA was amplified and subcloned into competent Escherichia coli cells using the TOPO TA Cloning Kit (Life Technologies) according to the manufacturer's directions. DNA was isolated from colonies using GenElute Mammalian Genomic DNA Miniprep kit (Sigma-Aldrich) and sequenced to confirm gene disruption through base-pair deletion and/or insertion and identification of specific homozygous KO clones.
mRNA Expression Analysis. Cells at subconfluent densities were trypsinized from T75 flasks and centrifuged at 800 rpm for 5 minutes. Medium was aspirated, and cell pellets were stored at 280°C until use. RNA from each of the cell pellets was isolated using the RNeasy Protect Mini Kit (Qiagen, Valencia, CA). To remove genomic DNA, on-column DNase digestion was performed using the On-Column DNase 1 digestion set (Sigma-Aldrich) according to instructions.
Reverse-transcription PCR reactions were set up using the Taqman RNA-to-C t 1
Step kit (Life Technologies) including individual transporter gene primers or endogenous control glyceraldehyde-3-phosphate dehydrogenase primers (Taqman Gene Expression Assays; Life Technologies) and 100 ng of RNA. PCR cycling conditions consisted of 48°C for 30 minutes, 95°C for 10 minutes, followed by 40 cycles of a denaturing step at 95°C for 15 seconds and an annealing/extension step with fluorescence monitoring at 60°C for 1 minute. The relative expression changes were calculated as described by Livak and Schmittgen (2001) .
Immunoblot Protein Expression Analysis. Confluent T75 flasks of Caco-2 cells were lysed with 2 ml of 1Â LDS sample buffer (Life Technologies) containing protease inhibitor cocktail. Cells were scraped from the flask, homogenized using Qiashredder columns (Qiagen), and stored at 280°C. Thawed lysates were denatured by heating for 10 minutes at 65°C, then loaded (20 ml per lane) onto NuPage Novex 4-12% Bis-Tris gels (Bio-Rad Laboratories, Hercules, CA) and run at 200 V in 4-morpholinepropanesulfonic acid SDS buffer. Gels were transferred to polyvinylidene fluoride membranes for 15 minutes using the Trans-Blot Turbo system (Bio-Rad). Membranes were blocked with Blotto containing 0.05% Tween (Blotto+T) for 2-3 hours while shaking at room temperature. Membranes were placed in Blotto+T containing primary antibodies (diluted 1:250, or 1:1000 for b-actin) and incubated at 4°C overnight while shaking. Following multiple 10-minute washes in Tris-buffered saline with 0.05% Tween, membranes were placed in Blotto+T containing anti-rabbit or anti-mouse secondary antibodies (diluted 1:10,000) and incubated for 1 hour while shaking. Following multiple 10-minute washes in Tris-buffered saline with 0.05% Tween, proteins were visualized using Super Signal West Dura detection reagent (Thermo Scientific, Rockford, IL) and imaged on a ChemiDoc imager using Image Laboratory software v4.0 (Bio-Rad).
Bidirectional Transport Assay. C2BBe1 wild-type and KO cell lines were plated at 4 Â 10 4 cells/well onto Costar HTS-Transwell 24-well permeable support plates (0.4-mM pore size, 0.33-cm 2 polyethylene terephthalate filter). Cells were cultured for 20-22 days to obtain differentiated monolayers with tight junctions and polarized transporter expression. On day of study, cell monolayers were rinsed twice and then preincubated for 30-60 minutes with transport buffer (Hanks' balanced salt solution with 25 mM D-glucose and 10 mM HEPES; pH 7.4) in both chambers at 37°C. Test articles were diluted from 10 mM dimethylsulfoxide stocks to 5 or 10 mM in transport buffer and placed in either apical (A) or basolateral (B) donor chambers in triplicate, while fresh transport buffer alone was placed in receiver chambers. Additional transport studies were conducted in the presence of inhibitors MK571 [5-(3-(2-(7-chloroquinolin-2-yl)ethenyl)phenyl)-8-dimethylcarbamyl-4,6-dithiaoctanoic acid], Ko143 [(3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino [19,29:1,6] pyrido [3,4-b] indole-3-propanoic acid 1,1-dimethylethyl ester], or verapamil, which were added to both chambers during transport assay at indicated concentrations. Plates were incubated at 37°C for 2 hours, at which time aliquots were removed from donor and receiver chambers for quantitation. Analyte concentrations were determined by liquid chromatographytandem mass spectrometry (LC-MS/MS).
For the fluorescent MRP2 substrate CDCF, plates were treated with 10 mM CDCFDA and incubated at 37°C for 2 hours as above. Receiver and donor chamber samples were transferred to black-walled 96-well plates. A triplicate standard curve of 2-fold serial dilutions from 10 mM CDCF was generated from a 10 mM dimethylsulfoxide stock. Plates were quantified by fluorescence at 485-nm emission, 538-nm excitation on a SpectraMax Gemini XS plate reader using SOFTmax Pro software v 3.1.2 (Molecular Devices, Sunnyvale, CA), both immediately postassay and after 24 hours at room temperature for maximal hydrolysis of dosing and donor solutions to fluorescent product.
At the conclusion of the transport assay, residual buffer was aspirated from all wells. Fresh transport buffer was added to basolateral chambers, and Lucifer yellow (dilithium salt) at 0.1 mg/ml in Hanks' balanced salt solution was added to apical chambers. The plates were incubated at 37°C for 1 hour. Samples were transferred from the basolateral chambers to black-walled 96-well plates and quantified by fluorescence at 485-nm emission, 538-nm excitation as described above. Lucifer yellow permeability A to B was calculated; those wells exhibiting permeability .2 Â 10 26 cm/s were eliminated from assay results.
LC-MS/MS Analysis. Concentration of test articles in samples was analyzed by LC-MS/MS using an API-4000 Q Trap mass spectrometer with a Turbo V atmospheric pressure electrospray ionization source (AB SCIEX, Framingham, MA). Samples (40 ml) were injected onto a Fortis C8 column (2.1 Â 50 mm, 5 mm) and eluted by a mobile phase gradient optimized for each test article [mobile phase A: 4 mM ammonium formate; mobile phase B: 4 mM ammonium formate in 90% (v/v) acetonitrile]. Flow rate was 0.5 ml/min. Using positive or negative ionization mode, analytes were quantitated using multiple reaction monitoring specific for each analyte and internal standard (tolbutamide) parent-product ion pairs. Peak areas of analyte and internal standard and resulting ratios were quantified using Analyst 1.5 (AB SCIEX).
Calculations. The apparent permeability (P app , in centimeters per second) was determined for both A to B and B to A directions by the following calculation:
in which A is the area of filter membrane, C D (0) is the initial concentration of the test drug, dM r is the amount of transported drug, and dt is time elapsed. The efflux ratio (ER) was calculated from ER ¼ ðP app; B to A Þ=ðP app; A to B Þ An efflux ratio of $2 suggests an active transport process, identifying the compound as an apical efflux transporter substrate. Statistics. Unless otherwise noted, all transport assays were carried out in triplicate and repeated on at least three separate days. The data are presented as mean 6 S.D. Statistical significance was determined using one-way analysis of variance calculations.
Results ZFN-Mediated Disruption of Genomic DNA Sequence. Following nucleofection with ZFN pairs and single cell sorting, C2BBe1 clones exhibiting mutations in all four alleles were initially identified by fragment analysis. These clones were further expanded for genomic DNA sequencing within the ZFN target area. Small insertions and/or deletions (indels) were confirmed within each allele in the tetraploid cells for each single and double KO clone. Genotype analysis of the single KO clones is shown in Table 1 . Each MDR1 and BCRP KO clone contained out-of-frame indels resulting in the generation of a premature stop codon. For the MDR1 KO clone, each allele contained a unique modification, while for BCRP KO, only two modified sequences were observed among the four alleles. The MRP2 KO clone contained two separate in-frame deletions (29, 236); however, these deletions overlapped a splice site and thus were still effective at disruption of translation into a functional MRP2 protein. The MDR1 KO, BCRP KO, and MDR1/BCRP KO clones were all generated independently; the MRP2 KO was used to generate the MDR1/ MRP2 KO and the MRP2/BCRP KO clones in a second round of ZFN nucleofections.
Protein Expression Analysis. Western blots were run to confirm the absence of the targeted transporter protein in each of the single KO clones (Fig. 1) . For each transporter, the protein was detected in the wild-type (parental) cells but was completely absent in the appropriate KO cell line. Equivalent loading of protein samples per lane was confirmed by measuring b-actin staining. mRNA Expression Analysis. To determine whether substantive changes in expression of related ABC transporters occurs when single or double transporter genes are knocked out, mRNA expression levels of MDR1, BCRP, MRP2, MRP3, and MRP4 were measured in each of the single and double KO cell lines. In Fig. 2A , relative mRNA expression levels of these five transporters are shown for each of the single KO cell lines compared with wild type (normalized to 1). As expected, the mRNA level of each target gene was reduced in its respective KO line, most likely due to decreased stability of the mutated transcript. Only small changes in expression levels were detected for any of the other transporters. Maximum changes detected were a 2-fold increase in MRP3 mRNA expression in BCRP KO cells and a 2-fold decrease in MRP3 mRNA expression in MDR1 KO cells. Similar modest compensatory changes were observed in the double KO cells (Fig. 2B) . Here, a 2.5-fold increase in expression of MRP3 mRNA was noted in the MDR1/MRP2 KO cells.
Cell Line Characterization. Each of the KO cell lines exhibited morphology and growth characteristics that were similar to the parental C2BBe1 cells, with the exception of a slight lag in growth rate for the MRP2 KO cell lines. The cellular phenotype for each KO cell line (loss of activity toward a model substrate) was stable out to at least 40 passages post generation of the master cell bank (data not shown); KO cells were not tested past 40 passages. All cell lines took a typical 21-day growth period to fully differentiate and form tight junctions on Transwell plates. Passive permeability data for two marker compounds, atenolol (low permeability, ,1 Â 10 26 cm/s) and metoprolol (high permeability, .15 Â 10 26 cm/s), were used to compare the passive permeability of wild-type cells with each KO cell line, and also to serve as a quality control when running test compounds in these assays. Passive permeabilities of both atenolol and metoprolol were similar in wild-type and all KO cell lines (data not shown). As an additional control used in all assays, Lucifer yellow A to B permeability was checked as a paracellular permeability marker postassay to ensure that tight junctions remained intact. Bidirectional Transport Activity Using Probe Substrates. The transport of probe substrates for each targeted transporter was examined in the full panel of KO cell lines generated, and results were compared with those achieved in the wild-type C2BBe1cells. The A to B and B to A permeability values and the resultant efflux ratios are shown in Tables 2-4. Efflux ratios for digoxin and erythromycin were reduced to near unity in the MDR1 single and double KO cell lines (Table 2 ). This was a reflection of both an increase in permeability in the A to B (absorptive) direction and a decrease in the B to A (secretory) direction. The use of transporter-specific inhibitors in the parental C2BBe1 cell line was compared with results obtained using KO cells. The P-gp inhibitor verapamil (100 mM) successfully inhibited digoxin and erythromycin efflux in wild-type cells to the same extent seen in the KOs. Surprisingly, digoxin permeability rates in the A to B direction were decreased somewhat in the BCRP, MRP2, and MRP2/BCRP KO cell lines (from 0.99 to ;0.25 Â 10 26 cm/s), while the B to A rates remained nearly unchanged (12.5 to 18.2 Â 10 26 cm/s). This resulted in higher efflux ratios for digoxin in these cell lines compared with wild type. Nitrofurantoin and estrone 3-sulfate were used as model substrates to test for loss of function in the BCRP KO cell lines. The efflux ratios for both compounds were reduced to near unity in the BCRP single and double KO cell lines (Table 3) . As a comparator, the BCRP inhibitor Ko143 (1 mM) reduced the efflux ratios for estrone sulfate For the MRP2 KO cell line, the nonfluorescent compound CDCFDA was used as the probe substrate. CDCFDA passively diffuses into cells, where it is hydrolyzed by intracellular esterases to the fluorescent product CDCF, which is then rapidly excreted by MRP2 (Siissalo et al., 2009 ). The CDCF efflux ratio was reduced to ;2 in the MRP2 single and double KO cell lines (Table 4 ). In contrast, the MRP2 inhibitor MK571 (25 mM) only partially inhibited CDCF transport, with an efflux ratio of .8 in wild-type cells.
Additional Test Compounds. To further probe the utility of these cell lines, several additional compounds (ranitidine, cimetidine, fexofenadine, and colchicine) were tested for transporter interactions. Ranitidine was identified as a substrate of P-gp only, based on loss of polarized transport in all MDR1 KO lines (Fig. 3) . In contrast, the efflux ratio for cimetidine was only partially reduced in both the MDR1 and BCRP single KO lines (Fig. 4) . However, in the MDR1/BCRP double KO cells, the efflux ratio was fully reduced to unity, thus identifying cimetidine as a substrate for both P-gp and BCRP. The P-gp and BCRP inhibitors verapamil and Ko143 gave a similar pattern of results. Verapamil fully inhibited ranitidine efflux, whereas Ko143 had no effect (Fig. 3) , confirming the role of P-gp as sole transporter. For cimetidine, a combination of either KO + inhibitor or both inhibitors, resulting in a cumulative loss of both P-gp and BCRP activity, was required to reduce the efflux to near unity (Fig. 4) .
Fexofenadine showed a slightly more complex picture of transporter interactions. In wild-type cells, the efflux ratio for fexofenadine was 5.11 (Fig. 5) . This was largely inhibited by verapamil (efflux ratio = 2.08) but not at all by MK571. In the KO panel, all cell lines lacking P-gp (i.e., MDR1, MDR1/BCRP, and MDR1/MRP2 KOs) showed a complete reduction in efflux, demonstrating that fexofenadine is a substrate for P-gp. In contrast, the BCRP, MRP2, and MRP2/BCRP KO cell lines did not show any inhibition of fexofenadine efflux except in the presence of verapamil. Similar to the parental cell line, addition of verapamil only partially reduced the efflux ratio in the KO cell lines. Notably, with each of the three MDR1 KO cell lines, the efflux ratio was reduced to ,1 (0.51-0.72), suggesting a net shift toward basolateral efflux, or absorptive transport, in the absence of P-gp. The addition of MK571 slightly increased the efflux ratio of fexofenadine in these KO cell lines (0.93-1.52), suggesting inhibition of the basolateral transport.
The colchicine efflux ratio in wild-type cells was 12.8; this efflux was completely inhibited in the KO cell lines lacking P-gp, but not in the other KO cell lines, clearly demonstrating that colchicine is a substrate for P-gp (Fig. 6 ). Similar to results seen with fexofenadine, the efflux ratio of colchicine in the MDR1 KO cells was slightly ,1 (efflux ratios between 0.88 and 0.96) and was also slightly increased in the presence of MK571 (1.0-1.4), again suggesting that a basolateral MRP is involved. In the cell lines expressing P-gp, both verapamil and MK571 partially affected colchicine transport when used alone and were able to fully inhibit colchicine efflux only when used in combination (efflux ratios between 1.4 and 2.1). However, the MRP or other target of MK571 is currently unknown. Effect of MK571 on Caco-2 Cell Permeability. To further investigate the role of MK571 in colchicine transport, we tested colchicine in the wild-type and single KO cell lines with MK571 at 0, 10, 25, and 100 mM. At 100 mM MK571, the colchicine efflux ratio in wild-type cells was reduced from .15 to ;1.2, suggesting total inhibition of active transport. However, the permeability of colchicine had increased significantly in both directions (data not shown), and the Lucifer yellow data from the postassay integrity control indicated a 12-to 16-fold-increased permeability in wells that had been exposed to 100 mM MK571. Additional assays were run using 10-100 mM MK571 under the same experimental conditions but in the absence of any other compound. We observed that Lucifer yellow A to B permeability increased significantly in C2BBe1 cells with concentrations of MK571 of $50 mM, to .10-fold higher at 100 mM (Fig. 7) ; similar results were seen in all KO cell lines.
Discussion
Clinically relevant drug-drug interactions have been associated with transporter inhibition, including efflux transporters (Giacomini et al., 2010) . In addition, interaction with efflux transporters has been linked to poor bioavailability and/or altered rates of clearance (Misaka et al., 2013) . Although several cell-based and membrane model systems exist for studying transporter interactions, these are typically dependent on the use of transporter-specific substrates and inhibitors, or they target a single transporter overexpressed in a nonhuman cell system that contains endogenous transporters and lacks the full complement of human transporters. To address some of the limitations of these current systems, we generated single and double KO cell lines for the ABC family efflux transporters P-gp, BCRP, and MRP2 in human intestinal C2BBe1 cells using ZFN gene editing technology. The KOs were confirmed by genetic analysis, Western blotting, and functional assays using model substrates. The KO cell lines appeared similar to the wild type in terms of growth rates and morphology, differentiation, formation of tight junctions, passive permeability of model compounds, and stability of phenotype.
A key concern in all KO models, whether in vivo or in vitro, is the potential for adaptation or compensation for the loss of the target gene by changes in the expression of related genes. To address this concern, we compared mRNA expression levels of the three efflux transporters as well as MRP3 and MRP4 in parental and all KO cell lines. Our data suggest little if any impact on the expression level of these transporters; however, only a few genes were examined in the present in vitro study, and the possibility of compensation at the protein expression level cannot be definitively ruled out. Comparative analyses have been carried out in rat models in which P-gp, BCRP, or MRP2 have been knocked out using ZFN technology (Chu et al., 2012; Huang et al., 2012; Zamek-Gliszczynski et al., 2013) . ZamekGliszczynski et al. (2013) reported that expression analyses of a set of 112 genes relevant to absorption, distribution, metabolism, and elimination in liver, kidney, intestine, and brain tissues of the three KO rat lines demonstrated only modest compensatory changes and did not preclude their general application to study transporter-mediated pharmacokinetics. Bidirectional transport studies were carried out in all KO cell lines using well characterized substrates specific for each individual transporter and comparing results with the wild-type cells. Compounds used included digoxin and erythromycin for P-gp, estrone sulfate and nitrofurantoin for BCRP, and CDCF for MRP2. Each KO cell line showed an appropriate reduction of efflux ratio with the representative substrate. Inhibitory effects were consistent between the single and double KO cell lines in which the same transporter was absent.
Several additional compounds, including some with known crossover between multiple transporters, were tested in the KO cell lines. Cimetidine has been reported to be a substrate for both P-gp and BCRP (Pavek et al., 2005; Taur and Rodriguez-Proteau, 2008) , while ranitidine is transported primarily by P-gp (Collett et al., 1999; Bourdet and Thakker, 2006) . Our results confirmed that cimetidine was a substrate of both P-gp and BCRP, as the efflux ratio was reduced to unity only in the MDR1/BCRP KO cell line, while ranitidine was identified as a substrate for P-gp alone. For both cimetidine and ranitidine, the inhibitors verapamil and Ko143 were equally effective at inhibiting the efflux ratio as the KO cells.
The H 1 antagonist fexofenadine has been described as a substrate for P-gp (Cvetkovic et al., 1999; Drescher et al., 2002) , although the possible involvement of multiple efflux transporters in its hepatic disposition, including MRP2, has been suggested (Matsushima et al., 2008; Tian et al., 2008) . In the present studies, fexofenadine was observed as a substrate for P-gp, as reduced efflux was clearly observed in the P-gp KO cell line whereas no reduction of efflux was observed in either the BCRP or MRP2 single KO cell lines. The KO cell lines provided a clearer assessment of interactions with transporters than did the use of chemical inhibitors, because verapamil was only able to reduce the efflux ratio for fexofenadine to 2.08, 4.20, and 2.74 in the wild-type, BCRP KO, and MRP2 KO cell lines, respectively. Interestingly, the efflux ratio for fexofenadine in the MDR1 KO cells was significantly ,1 (0.51), suggesting absorptive transport. This was also observed in the two double KO cell lines that lacked functional P-gp. The potential involvement of a basolateral efflux transporter in the MRP family is supported by the observation that the addition of MK571 increased the efflux ratio in each of the cell lines lacking P-gp (up to 1.52 in the case of MDR1 KO cells). These data support the conclusions drawn by Ming et al. (2011) that fexofenadine apical efflux in Caco-2 cells is predominantly mediated by P-gp, whereas basolateral efflux is predominantly mediated by MRP3. Based on data using MK571 and a P-gp/BCRP inhibitor (GW120918), Ming et al. (2011) further suggested that MRP2 makes a small contribution to the apical efflux of fexofenadine, although our data using the MRP2 KO cell lines do not support the involvement of MRP2.
Similar results were found for the microtubule polymerization inhibitor colchicine. We observed that colchicine was a substrate for P-gp, based on reduction in efflux ratio in the P-gp KO cell lines and lack of effect in the other KO cell lines. Similarly to fexofenadine, the efflux ratios in cell lines lacking P-gp were below unity, but were slightly increased by addition of MK571, suggesting that a basolateral MRP may interact with colchicine in the absence of P-gp. Colchicine has been reported as a substrate for both P-gp and MRP2 in Caco-2 cells and rodent intestine (Dahan et al., 2009) ; however, our data do not support colchicine interaction with MRP2. Reasons for this discrepancy in results may include the lack of MK571 specificity within the MRP family as well as a negative impact on the Caco-2 cell monolayer at higher concentrations, and point to the challenges in using chemical inhibitors versus gene KO technology. Experiments were carried out with MK571 in both chambers at concentrations of 10-100 mM in Transwell plates for 2 hours at 37°C, followed by Lucifer yellow assay for 1 hour at 37°C. Values represent Lucifer yellow permeability mean 6 S.D.; n = 9-10 in each experimental group. Statistical significance was determined by oneway analysis of variance. ***P , 0.001 versus untreated control.
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In the present experiments, inhibitors gave equivalent results in wild-type cells compared with the KO cells (full inhibition of efflux) for ranitidine and cimetidine, but not for fexofenadine or colchicine, suggesting substrate dependence as another obstacle when using chemical inhibition in transport interpretations. The KO cell lines represent complete inhibition of the targeted transporter and are an efficient alternative to the suggested use of multiple substrates and inhibitors to ensure coverage of multiple binding sites, substrate specificity, and affinity that may occur when characterizing transporter interactions in vitro (Brouwer et al., 2013) .
The problem of inadequate specificity for inhibitors used in transporter assays has been well documented. For example, Matsson et al. (2009) reported that each of the inhibitors used in the current study (verapamil, Ko143, and MK571) have varying degrees of overlap with other efflux transporters at higher concentrations, but were chosen for these studies due to their common use and commercial availability. Although nonselectivity can be partially addressed by carefully choosing the inhibitor concentration, it is difficult to accurately assess the intracellular concentration of inhibitor at the transporter site. The most promiscuous of the three, MK571, has IC 50 s of 10, 26, and 50 mM for MRP2, P-gp, and BCRP, respectively (Matsson et al., 2009 ). In addition, our results and the work of others suggest that MK571 inhibits not only MRP2 but other MRPs, although potencies have not been established. Virtual docking experiments have shown that MK571 binds to the ATP catalytic site, which may contribute to its relatively nonspecific inhibition profile (Matsson et al., 2009 ). Because MK571 is often used at 50 mM or higher concentrations in the literature, offtarget effects should be anticipated. Furthermore, we found that MK571 negatively affects passive permeability within the cell monolayer when used at 50 mM or higher, further complicating the interpretation of transporter experiments with this inhibitor.
In comparison with other formats for studying drug-transporter interactions, KO cell lines provide a new and complementary approach to determine the profile of efflux transporters with which a given compound may interact. These cell lines were generated from a human parental line (Caco-2) extensively used for transporter studies for .2 decades. This offers the advantage of the presence of the full complement of other relevant human transporters in the same cell system, while avoiding potential contributions from nonhuman transporters (Kuteykin-Teplyakov et al., 2010) . In addition, the double KO cell lines can be used to confirm effects seen in the single KO cells or to study the remaining apical efflux transporter in relative isolation.
In summary, we have generated stable MDR1, BCRP, and MRP2 single and double KO Caco-2 cell lines using ZFN technology. These KO cell lines show complete loss of transporter function using specific substrates in the bidirectional transport assay format and are useful in identifying specific drug-transporter interactions by comparison of transport between the wild-type and KO lines. These cell lines represent a valuable tool for application in the assessment of drug-transporter interactions without dependence on chemical inhibitors with poorly defined specificities or RNA knockdown systems with residual activities.
